AR082005A1 - Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino - Google Patents
Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platinoInfo
- Publication number
- AR082005A1 AR082005A1 ARP110102109A ARP110102109A AR082005A1 AR 082005 A1 AR082005 A1 AR 082005A1 AR P110102109 A ARP110102109 A AR P110102109A AR P110102109 A ARP110102109 A AR P110102109A AR 082005 A1 AR082005 A1 AR 082005A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- derivative
- antitumor
- ombrabulin
- platinum
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 abstract 3
- 229950003600 ombrabulin Drugs 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 2
- 239000005022 packaging material Substances 0.000 abstract 2
- 150000003057 platinum Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 208000037844 advanced solid tumor Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino, estando estos componentes terapéuticos en la forma de una base libre o de una sal de adición con un ácido farmacéuticamente aceptable, o en la forma de un hidrato o de un solvato, en la que esta combinación antitumoral se tolera bien, no exacerba la toxicidad de cada uno de los agentes antitumorales y que permite el tratamiento de tumores sólidos avanzados bien estabilizando o induciendo una regresión parcial o completa del tumor.Reivindicación 5: Combinación según una cualquiera de las reivindicaciones 1 a 4 en la que la ombrabulina está en combinación con docetaxel y cisplatino o en combinación con paclitaxel y carboplatino. Reivindicación 18: Artículo de fabricación que comprende: un material de envasado; una combinación farmacéutica antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino, estando estos agentes en la forma de una base libre o de una sal de adición con un ácido farmacéuticamente aceptable, o en la forma de un hidrato o de un solvato; y una etiqueta o prospecto contenido en dicho material de envasado que indica que dicha combinación farmacéutica antitumoral se administra al paciente a una dosis recomendada, y en varias dosis posteriores a una dosis recomendada separadas entre sí en el tiempo tres semanas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305653A EP2397135A1 (en) | 2010-06-18 | 2010-06-18 | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| EP10306256A EP2481404A1 (en) | 2010-11-15 | 2010-11-15 | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082005A1 true AR082005A1 (es) | 2012-11-07 |
Family
ID=45347705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102109A AR082005A1 (es) | 2010-06-18 | 2011-06-17 | Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130122113A1 (es) |
| EP (1) | EP2582369A1 (es) |
| JP (1) | JP2013528644A (es) |
| KR (1) | KR20130088753A (es) |
| CN (1) | CN103140224A (es) |
| AR (1) | AR082005A1 (es) |
| AU (1) | AU2011266635A1 (es) |
| BR (1) | BR112012031917A2 (es) |
| CA (1) | CA2802974A1 (es) |
| CO (1) | CO6650420A2 (es) |
| DO (1) | DOP2012000305A (es) |
| EA (1) | EA201291268A1 (es) |
| EC (1) | ECSP12012343A (es) |
| MA (1) | MA34380B1 (es) |
| MX (1) | MX2012014732A (es) |
| NI (1) | NI201200183A (es) |
| PE (1) | PE20130312A1 (es) |
| PH (1) | PH12012502483A1 (es) |
| SG (1) | SG186376A1 (es) |
| TN (1) | TN2012000552A1 (es) |
| TW (1) | TW201206419A (es) |
| UY (1) | UY33457A (es) |
| WO (1) | WO2011158206A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| EP1068870B1 (en) | 1998-04-03 | 2006-06-07 | Ajinomoto Co., Inc. | Antitumor agents |
| US20020183266A1 (en) | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| FR2838437B1 (fr) | 2002-04-11 | 2004-06-04 | Aventis Pharma Sa | Procedes de preparation de combretastatines |
| FR2945210B1 (fr) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
-
2011
- 2011-06-16 MA MA35567A patent/MA34380B1/fr unknown
- 2011-06-16 WO PCT/IB2011/052628 patent/WO2011158206A1/en not_active Ceased
- 2011-06-16 EP EP11738298.6A patent/EP2582369A1/en not_active Withdrawn
- 2011-06-16 MX MX2012014732A patent/MX2012014732A/es not_active Application Discontinuation
- 2011-06-16 CN CN2011800398329A patent/CN103140224A/zh active Pending
- 2011-06-16 SG SG2012092763A patent/SG186376A1/en unknown
- 2011-06-16 EA EA201291268A patent/EA201291268A1/ru unknown
- 2011-06-16 CA CA2802974A patent/CA2802974A1/en not_active Abandoned
- 2011-06-16 AU AU2011266635A patent/AU2011266635A1/en not_active Abandoned
- 2011-06-16 BR BR112012031917A patent/BR112012031917A2/pt not_active IP Right Cessation
- 2011-06-16 KR KR1020127032877A patent/KR20130088753A/ko not_active Withdrawn
- 2011-06-16 PH PH1/2012/502483A patent/PH12012502483A1/en unknown
- 2011-06-16 PE PE2012002429A patent/PE20130312A1/es not_active Application Discontinuation
- 2011-06-16 JP JP2013514831A patent/JP2013528644A/ja not_active Withdrawn
- 2011-06-17 TW TW100121314A patent/TW201206419A/zh unknown
- 2011-06-17 UY UY0001033457A patent/UY33457A/es unknown
- 2011-06-17 AR ARP110102109A patent/AR082005A1/es unknown
-
2012
- 2012-11-23 TN TNP2012000552A patent/TN2012000552A1/en unknown
- 2012-12-06 DO DO2012000305A patent/DOP2012000305A/es unknown
- 2012-12-07 NI NI201200183A patent/NI201200183A/es unknown
- 2012-12-18 US US13/718,335 patent/US20130122113A1/en not_active Abandoned
- 2012-12-18 CO CO12228676A patent/CO6650420A2/es not_active Application Discontinuation
- 2012-12-18 EC ECSP12012343 patent/ECSP12012343A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012031917A2 (pt) | 2017-11-28 |
| JP2013528644A (ja) | 2013-07-11 |
| MX2012014732A (es) | 2013-01-22 |
| PH12012502483A1 (en) | 2013-03-25 |
| EA201291268A1 (ru) | 2013-04-30 |
| TW201206419A (en) | 2012-02-16 |
| US20130122113A1 (en) | 2013-05-16 |
| AU2011266635A1 (en) | 2013-01-10 |
| MA34380B1 (fr) | 2013-07-03 |
| DOP2012000305A (es) | 2013-01-31 |
| NI201200183A (es) | 2013-05-13 |
| TN2012000552A1 (en) | 2014-04-01 |
| WO2011158206A1 (en) | 2011-12-22 |
| EP2582369A1 (en) | 2013-04-24 |
| CA2802974A1 (en) | 2011-12-22 |
| KR20130088753A (ko) | 2013-08-08 |
| SG186376A1 (en) | 2013-01-30 |
| CO6650420A2 (es) | 2013-04-15 |
| CN103140224A (zh) | 2013-06-05 |
| PE20130312A1 (es) | 2013-03-26 |
| ECSP12012343A (es) | 2012-12-28 |
| UY33457A (es) | 2012-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| UY34974A (es) | Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| UA107112C2 (uk) | Активатори розчинної гуанілатциклази | |
| DOP2010000011A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| MX2018012901A (es) | Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1). | |
| CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
| ECSP109934A (es) | Compuesto - 946 | |
| CR11200A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k | |
| BR112015007647A2 (pt) | derivados de quetamina | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| AR091233A1 (es) | Composicion farmaceutica que comprende abediterol | |
| CO7160008A2 (es) | Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| CY1119036T1 (el) | Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide | |
| MX394367B (es) | Moléculas tipo esfingolípidos sintéticas, fármacos, métodos de su síntesis y usos de los mismos. | |
| DOP2014000030A (es) | Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| AR082005A1 (es) | Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino | |
| AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |